Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210582 | 0.85 | NPC1 (0.56) | NPC1RAB9AHTR7CTNNB1KMT2A | |
| SCHEMBL6285905 | 0.83 | MAPT (0.49) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7210384 | 0.82 | GSR (0.49) | NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3215720 | 0.82 | RAB9A (0.53) | NPC1RAB9AHTR7CTNNB1KMT2A | |
| SCHEMBL7284408 | 0.72 | NPC1 (0.54) | NPC1RAB9ACTNNB1KMT2AMEN1 | |
| SCHEMBL5453020 | 0.72 | NPC1 (0.60) | NPC1RAB9AHTR7KMT2AMEN1 | |
| SCHEMBL21747253 | 0.70 | NPC1 (0.55) | NPC1RAB9ACTNNB1KMT2AMEN1 | |
| SCHEMBL26584242 | 0.70 | NPC1 (0.82) | NPC1RAB9AHTR7CTNNB1KMT2A | |
| SCHEMBL3392114 | 0.69 | KMT2A (0.51) | KMT2AMEN1KCNH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL7287642 | 0.69 | KMT2A (0.53) | NPC1RAB9AKMT2AMEN1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-6815460-B2 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2004-11-09 | — | — | US | disclosed |
| EP-1369415-A1 | Substituted pyrrolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-5935990-A | PYRROLYL DERIVATIVES HAVING AT POSITION 1 OR 5 A PHENYL SUBSTITUTED WITH METHYLSULFONYL OR AMINOSULFONYL; INHIBIT CYCLOOXYGENASE-2 FOR USE TREATMENT OF INFLAMMATION, AS AN ANALGESIC, OR AS AN ANTIPYRETIC | G.D. SEARLE & CO. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5932598-A | NOVEL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PRODRUGS; ADMINISTERING TO TREAT INFLAMMATION-ASSOCIATED PAIN DUE TO CANCER, DENTAL PAIN; CYCLOOXYGENASE-2 INHIBITORS | G. D. SEARLE & CO. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | NPC1 3989/4885RAB9A 4254/4885HTR7 1316/4885 |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PTGS2, PTGES2, PTGES | NPC1 3894/4885RAB9A 4116/4885HTR7 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.